<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858037</url>
  </required_header>
  <id_info>
    <org_study_id>MTN-025</org_study_id>
    <nct_id>NCT02858037</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women</brief_title>
  <official_title>A Phase 3B Open-Label Follow-on Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV Open-label Prevention Extension (HOPE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 3B Open-Label Follow-on Trial to Assess the Continues Safety of and Adherence to a
      Vaginal ring Containing Dapivirine in Women
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to be replaced each month for a total period of 12 months of use.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing the Dapivirine Ring open label use Safety Profile by Grade 2, Grade 3 and all serious AEs</measure>
    <time_frame>13 months</time_frame>
    <description>To characterize the safety profile associated with the open label use of the dapivirine vaginal matrix ring (25 mg) in women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>By measuring the residual levels of dapivirine in returned vaginal rings and Blood dapivirine levels</measure>
    <time_frame>13 months</time_frame>
    <description>To characterize adherence to the open label use of the dapivirine vaginal matrix ring (25 mg) in women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 infection as measured by the protocol algorithm</measure>
    <time_frame>13 months</time_frame>
    <description>To assess incidence of HIV-1 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 drug resistance mutations among participants who acquire HIV-1, as measured by standard genotype analysis and more sensitive methods to detect low frequency drug-resistant variants</measure>
    <time_frame>13 months</time_frame>
    <description>To assess the frequency of HIV-1 drug resistance in women who acquire HIV-
1 infection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>HIV Open-label Prevention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following demonstration of safety and efficacy of the dapivirine vaginal ring in MTN-020, eligible MTN-020 participants will be offered enrollment into MTN-025, a trial designed to obtain additional safety and adherence data in women</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Dapivirine Vaginal Ring</intervention_name>
    <description>Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.</description>
    <arm_group_label>HIV Open-label Prevention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women must meet all of the following criteria to be eligible for inclusion in the study

          1. Previously enrolled in MTN-020 (ASPIRE)

          2. Able and willing to provide written informed consent to be screened for and to take
             part in the study

          3. Able and willing to provide adequate locator information, as defined in site SOPs

          4. HIV-uninfected based on testing performed by study staff at Screening and Enrollment

          5. Using an effective method of contraception at Enrollment, and intending to use an
             effective method for the duration of study participation; effective methods include
             hormonal methods (except contraceptive ring); intrauterine contraceptive device
             (IUCD); and sterilization (of participant, as defined in site SOPs)

          6. At Screening and Enrollment, agrees not to participate in other research studies
             involving drugs, medical devices, vaginal products, or vaccines for the duration of
             study participation

        Exclusion Criteria:

        Women who meet any of the following criteria will be excluded from the study

          1. Study product use permanently discontinued in response to an AE or safety related
             concern while taking part in the MTN-020 (ASPIRE) trial

          2. Per participant report at Screening:

               1. Plans to relocate away from the study site during study participation

               2. Plans to travel away from the study site for more than three consecutive months
                  during study participation

          3. Per participant report at Enrollment, currently taking Post-Exposure Prophylaxis (PEP)

          4. With the exception of MTN-020 (ASPIRE), participation in any other research study
             involving drugs, medical devices, vaginal products, or vaccines, within 60 days of
             enrollment

          5. Is pregnant at Screening/Enrollment or planning to become pregnant in the
             participant's anticipated study participation period

          6. Currently breastfeeding

          7. Diagnosed with urinary tract infection (UTI), pelvic inflammatory disease (PID), STI
             or reproductive tract infection (RTI) requiring treatment per WHO guidelines

          8. At Screening, has a clinically apparent Grade 3 pelvic exam finding (observed by study
             staff) as per the Division of AIDS Table for Grading the Severity of Adult and
             Pediatric Adverse Events Version 1.0, December, 2004 (Clarification dated August
             2009), Addendum 1-Female Genital Grading Table for Use in Microbicide Studies

          9. Has any of the following laboratory abnormalities at Screening Visit:

               1. Aspartate aminotransferase (AST) or alanine transaminase (ALT) &gt; Grade 3*

               2. Creatinine &gt; Grade 3*

               3. Hemoglobin &gt; Grade 3*

               4. Platelet count &gt; Grade 3*

               5. Pap result â‰¥ Grade 3 according to the Female Genital Grading Table for Use in
                  Microbicide Studies Addendum 1 to the DAIDS Table for Grading Adult and Pediatric
                  Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009)

         10. Has any significant medical condition or other condition that, in the opinion of the
             IoR/designee, would preclude informed consent, make study participation unsafe,
             complicate interpretation of study outcome data, or otherwise interfere with achieving
             the study objectives
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prevention for HIV and AIDS Project</name>
      <address>
        <city>Pinetown</city>
        <state>KwaZulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jared Baeten, MD, PHD</last_name>
      <phone>206-520-3808</phone>
      <email>jbaeten@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nyaradzo Mgodi, MBCHB, MMed</last_name>
      <phone>+263 4 704 920</phone>
      <email>nmmgodi@uz-ucsf.co.zw</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Derek Arbuckle</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Mickel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

